US Broker Ratings

Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring a Potential 248% Upside in the Biotech Sector

Nuvation Bio Inc. (NUVB) is capturing the attention of investors with a remarkable potential upside of 248.15%, according to analyst ratings. Operating within the dynamic biotechnology..

Beta Bionics, Inc. (BBNX) Stock Analysis: Potential 61% Upside in the Healthcare Sector

Beta Bionics, Inc. (BBNX), a promising player in the healthcare sector, is steadily capturing investor interest with its innovative solutions in the medical devices industry. Specializing..

Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a Promising 43.45% Potential Upside in the Healthcare Sector

Delcath Systems, Inc. (NASDAQ: DCTH) stands out in the medical devices industry with its innovative approach to treating liver cancers. Known for its HEPZATO KIT, this..

Gyre Therapeutics, Inc. (GYRE) Investor Outlook: Unpacking the 78.41% Potential Upside

In the ever-evolving landscape of the biotechnology sector, Gyre Therapeutics, Inc. (NASDAQ: GYRE) has positioned itself as a notable player, developing innovative therapies to combat debilitating..

Immunome, Inc. (IMNM) Stock Analysis: Unpacking the 189.60% Potential Upside

Immunome, Inc. (NASDAQ: IMNM), a clinical-stage biotechnology firm, is making waves in the healthcare sector with a promising pipeline aimed at developing targeted cancer therapies. With..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a Promising 58% Upside Potential

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is generating significant buzz among investors, promising a potential upside of 58.13%. This biopharmaceutical company, headquartered in Solana Beach, California, is..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: Exploring a Biotech Gem with 12.20% Potential Upside

Niagen Bioscience, Inc. (NAGE), a Los Angeles-based biotech company specializing in healthy aging products, has been catching the eye of investors with its promising potential upside..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Biotechnology Innovator with a 242% Potential Upside

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is making waves in the healthcare sector with its innovative approach to treating chronic cough in patients with idiopathic pulmonary fibrosis..

Pharvaris N.V. (PHVS) Stock Analysis: Potential 107.91% Upside Amid Biotech Advancements

Pharvaris N.V. (PHVS), a promising player in the biotechnology sector, is attracting substantial investor attention with a potential upside of 107.91%, according to analyst ratings. As..

Bicara Therapeutics Inc. (BCAX) Investor Outlook: Exploring a 108% Potential Upside in Biotech Innovation

Bicara Therapeutics Inc. (NASDAQ: BCAX), a burgeoning name in the biotechnology sector, stands at an intriguing juncture for investors looking to capitalize on its innovative approach..

Day One Biopharmaceuticals, Inc. (DAWN) Stock Analysis: Exploring a Potential 346% Upside

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a burgeoning player in the biotechnology sector, is attracting significant attention from investors due to its promising pipeline and the..

CareDx, Inc. (CDNA) Stock Analysis: A 71% Upside Potential Awaits Investors

CareDx, Inc. (NASDAQ: CDNA), a prominent player in the healthcare sector specializing in diagnostics and research, has captured investor attention with its innovative solutions for transplant..

Nutex Health Inc. (NUTX) Stock Analysis: Exploring a 53% Upside Potential with Robust Revenue Growth

Nutex Health Inc. (NUTX), a dynamic player in the healthcare sector, has captured investor attention with its robust revenue growth and significant upside potential. Despite recent..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Navigating the Challenges with a Strategic Outlook

Phibro Animal Health Corporation (NASDAQ: PAHC) presents a nuanced opportunity for investors in the healthcare sector, particularly within the niche of drug manufacturers for specialty and..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: A Bold Bet with 220% Potential Upside

Arcus Biosciences, Inc. (NASDAQ: RCUS), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its ambitious cancer therapy pipeline. Specializing in the development..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: A Biotech Contender with 154.94% Potential Upside

Praxis Precision Medicines, Inc (NASDAQ: PRAX) is carving a niche in the biotechnology sector with its focus on central nervous system (CNS) disorders. As a clinical-stage..

Cronos Group Inc. (CRON) Stock Analysis: Revenue Growth Amid Potential Downsides

Cronos Group Inc. (NASDAQ: CRON), a key player in the healthcare sector’s specialty and generic drug manufacturing industry, has been making waves with its focus on..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unveiling a 203% Potential Upside in the Biotech Arena

For investors with a keen eye on the biotech sector, Nurix Therapeutics, Inc. (NASDAQ: NRIX) presents a compelling opportunity. The company’s focus on innovative small molecule..

InMode Ltd. (INMD) Stock Analysis: Exploring a 20% Potential Upside in the Medical Devices Sector

InMode Ltd. (NASDAQ: INMD), a prominent player in the medical devices sector, is capturing the attention of investors with its innovative aesthetic medical products and a..

Enliven Therapeutics (ELVN) Stock Analysis: Exploring a 123% Potential Upside in Biotech

Enliven Therapeutics, Inc. (NASDAQ: ELVN) presents a compelling opportunity for investors seeking exposure to the biotechnology sector. With a market capitalization of $822.89 million, this clinical-stage..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds